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Solid organ transplantation (SOT) followed by hematopoietic cell transplantation (HCT) has been used to treat
a single disease with multiorgan involvement or 2 separate diseases, the ﬁrst requiring SOT and the second
often a possible complication of SOT. Results of such serial transplants have been reported sporadically in the
literature, usually as single case studies. Thirteen autologous and 27 allogeneic HCTs after SOT published
previously are summarized. A more detailed review is provided for an additional 16 patients transplanted at a
single institution, 8 of whom had autologous and 8 of whom had allogeneic HCT after SOT. Five of 8 autol-
ogous transplant recipients are alive a median of 4.6 years after HCT. Four of 8 allogeneic HCT recipients are
alive a median of 8.7 years after HCT. In carefully selected patients, HCT after SOT is feasible and associated
with a low incidence of either solid organ or hematopoietic cell rejection.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION grafts. HCT patients received either autologous or allogeneic bone marrow,
The indications for hematopoietic cell transplantation
(HCT) after solid organ transplantation (SOT) are varied.
A sequential SOT and HCT approach is sometimes used to
treat 1 disease, such as inborn errors of metabolism or
multiorgan failure secondary to viral infection or toxin
exposure. HCT has also been used for SOT patients who
develop a life-threatening hematologic disorder after SOT,
for example, a post-transplant lymphoproliferative disorder
(PTLD) unresponsive to standard therapy. Concerns exist that
(1) transplanted solid organs may be unusually sensitive to
the high-dose therapies often used with HCT, (2) the graft-
versus-host reaction seen after allogeneic HCT might put a
solid organ graft at risk, and (3) the presence of a solid organ
graft before allogeneic HCT might increase the chance of
rejection of the hematopoietic graft. To address these con-
cerns, we reviewed both published data and our own expe-
rience with HCT after SOT.
METHODS
Patients
A MEDLINE search of data published in English identiﬁed informative
patients. SOT patients included recipients of heart, lung, liver, or kidneydgments on page 2127.
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ty for Blood and Marrow Transplantation.peripheral blood stem cells (PBSC), or umbilical cord blood. Patients were
excluded if (1) they received SOT in conjunction with allogeneic stem cell
infusions from the solid organ donor to augment donor-speciﬁc tolerance in
the recipient [1,2] or (2) they underwent planned, sequential autologous
HCT before or after SOT for treatment of a single disease [3-9].
A retrospective analysis was performed for HCT patients at the Fred
Hutchinson Cancer Research Center (FHCRC) who had a prior SOT per-
formed either locally or at an outside institution. These patients were not
identiﬁed in our established databases; therefore, faculty and staff identiﬁed
informative patients. Between 1989 and 2012, 16 patients were identiﬁed, 8
who received autologous transplants and 8 who received allogeneic trans-
plants. One of these patients was reported previously [10].
Protocols and consent forms were approved by the Institutional Review
Board of the FHCRC, and informed consent was obtained from all patients
and donors. Information regarding the solid organ donors for the FHCRC
patients was obtained from patients’ medical records and from the Organ
Procurement and Transplantation Network database.
RESULTS
Autologous HCT after SOT
In the medical literature 13 patients were identiﬁed who
received autologous HCT after SOT (Table 1). These patients
were transplanted between 1994 and 2009. Median patient
age at the time of SOT was 37 years. Eight patients had liver
transplants, and 5 had kidney transplants, 1 of whom also
had a concurrent pancreatic transplant. One of these patients
had 2 kidney transplants, the second occurring 5.8 years after
rejection of the ﬁrst kidney [21]. Indications for SOT are
noted in Table 1. Eleven transplants were from cadaveric
donors, and 2 partial liver transplants were from parental
Table 1
Autologous HCT after SOT
Literature
Review
FHCRC
No. of patients 13 8
Gender: male/female 10/3 7/1
Age at SOT, yr
Median, range 37 (1.7-65) 52.5 (22-69)
No. solid organ transplants/patient
1 11 7
2 2 1
Indication for ﬁrst SOT
Liver
Alcoholic cirrhosis [11] 2 1
Biliary atresia [12] 1
Biliary cirrhosis [13] 1
Amyloidosis [14] 1
Hepatoblastoma [15] 1
Nonviral hepatitis [16] 1
Hepatitis B [17] 1
Autoimmune hepatitis 1
Kidney
Glomerulonephritis/
glomerulosclerosis [18,19]
2
Interstitial nephritis [20] 1
Polycystic kidney [21] 1
Congenital atrophy 1
Kidney þ pancreas
Juvenile diabetes mellitus [21] 1
Heart
Amyloidosis 1
Viral cardiomyopathy 2
Ischemic cardiomyopathy 1
Lung
Cystic ﬁbrosis 1
Solid organ donor
Cadaver 11 8
Parent 2 0
IST for SOT
CSP 1
CSP þ prednisone þ/ other* 5
CSP þ MMF þ/ prednisone 1 2
Tacrolimus 1
Tacrolimus þ prednisone 2 1
Tacrolimus þ prednisone þ sirolimus 1
Tacrolimus þ prednisone þ MMF þ/
othery
2 3
Tacrolimus þ azacitidine 1
Everolimus 1
Duration SOT to hematologic
diagnosis, yrz
Median, range 3.0 (0-14) 6.0 (.9-9.7)
Duration SOT to HCT, yrx
Median, range 3.5 (.2-15) 7.0 (1.3-11.9)
Hematologic diagnosis
Aplastic anemia 1
Amyloidosis 1 1
Metastatic hepatoblastoma 1
PTLD
DLBCL, EBV negative 1 1
DLBCL, EBV positive 2 2
DLBCL, EBV unknown 3
Multiple myeloma 2 1
Multiple myeloma þ MALT lymphoma 1
Plasmacytoma 1
Primary CNS B cell lymphoma, EBV
positive
1
T-PTLD, EBV negative 1
Relapsed B cell lymphoma 1
HCT conditioning regimen
Melphalan 6 2
Melphalan þ thiotepa þ/ other 1 2
BEAM 2 4
Mini-BEAM 2
BFAM 1
ATG, CSP, prednisone 1
(Continued)
Table 1
(continued)
Literature
Review
FHCRC
Stem cell source
PBSC 10 8
Bone marrow 1
Cord blood 1
Not stated 1
IST after HCT
Prednisone 1
Prednisone þ CSP 1
Sirolimus þ prednisone 1
Sirolimus 1
Tacrolimus 1
None 1 7
Not stated 8
Survival after ﬁrst HCT, yr
Median, range 2.0 (.5-5.0) 3.4 (0.1-5.5)
Cause of death
Relapsed lymphoma 1 2
Cardiac rejection 1
CSP indicates cyclosporine; MMF, mycophenolate mofetil; DLBCL, diffuse
large B cell lymphoma; EBV, Epstein-Barr virus; MALT, mucosa-associated
lymphoid tissue; CNS, central nervous system; BEAM, carmustine þ
etoposide þ cytarabine þ melphalan; BFAM, carmustine þ ﬂudarabine þ
cytarabine þ melphalan; ATG, antithymocyte globulin; OKT3, muromonab
CD3.
* ATG ¼ 1; azathioprine ¼ 2.
y ATG ¼ 2; OKT3 ¼ 1; daclizumab ¼ 1.
z Data not available for 1 patient.
x Data not available for 2 patients.
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SOT included a corticosteroid and a calcineurin inhibitor.
SOT and HCT treated the same disease in 2 patients: 1 had
amyloidosis and 1 had metastatic hepatoblastoma. Eleven
patients developed new hematologic diagnoses: PTLD (n ¼
9), relapsed B cell lymphoma (n ¼ 1), and aplastic anemia
(AA; n ¼ 1). The median time from SOT to the hematologic
diagnosis was 3.0 years. The median time from SOT to
autologous HCT was 3.5 years.
Autologous transplant conditioning regimens were
melphalan-based, except in the patient with AA. The source
of hematopoietic stem cells was PBSCs in 10 patients, bone
marrow in 1 patient, and cryopreserved cord blood in the
patient with AA. (The stem cell source was unknown for 1
patient.) Twelve patients were reported alive at .5 to 5 years
after HCT. One patient died 10 months after HCT of recurrent
lymphoma.
Between May 2004 and June 2011, 8 FHCRC patients un-
derwent autologous HCT after SOT (Table 1 and
Supplementary Table 1). Median patient age at SOT was 52.5
years. All patients received cadaveric solid organs a median
of 7.0 years before HCT. Four patients had heart transplants
for cardiomyopathies. Two patients received liver trans-
plants, 1 for autoimmune hepatitis and 1 for alcoholic
cirrhosis. One patient had a kidney transplant for congenital
atrophic kidneys, and 1 had a double-lung transplant for
cystic ﬁbrosis. All patients received a calcineurin inhibitor
plus 1 to 3 additional drugs for immunosuppression at the
time of SOT.
In 7 patients the indication for HCT was PTLD (diffuse
large B cell lymphoma [n ¼ 6] and a plasma cell dyscrasia
[n ¼ 1]). The remaining patient (patient 1, Supplementary
Table 1) had primary amyloidosis and received a heart
transplant followed by 2 autologous HCTs, .4 and 2.2 years
after the heart transplant. The median time from the
Table 2
Allogeneic HCT after SOT
Literature
Review
FHCRC
No. of patients 27 8
Gender: male/female 19/8 3/5
Age at SOT, yr
Median, range 10.0 (.2-74) 15.6 (1.0-48)
No. SOTs/patient
1 27 7
2 1
Indication for SOT
Heart
Cardiomyopathy [22,23] 2
Atherosclerotic cardiovascular
disease [24]
1
Anthracycline toxicity [25] 1
Hypoplastic left heart [23] 1
Liver
Nonviral hepatitis [10,26-32] 7 1
Nonspeciﬁc hepatitis [23,33] 3
Hepatitis C [34,35] 2
EPP [36,37] 2
HLH [38] 1
Budd-Chiari second degree to
polycythemia vera [39]
1
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was 1.0 year. All patients received melphalan-based condi-
tioning regimens, followed by PBSC infusions, and all pa-
tients achieved engraftment. One patient (patient 2,
Supplementary Table 1) died 3 years after HCT from cardiac
rejection and renal failure. Two heart transplant recipients
died of persistent PTLD, .07 and .31 years after HCT. Five
patients were alive as of the date of last contact. The lung
transplant recipient developed bronchiolitis obliterans and is
awaiting a second lung transplant. Median survival after HCT
for all 8 patients is 3.4 years.
Three patients were successfully treated for rejection
episodes of their SOT (heart ¼ 2, liver ¼ 1) before autologous
transplantation. One of the heart transplant recipients
(patient 2, Supplementary Table 1) had an episode of rejec-
tion when IST was held while administering chemotherapy
for PTLD. A second heart transplant recipient (patient
4, Supplementary Table 1), who also had a kidney transplant,
had 2 episodes of cardiac rejection successfully treated
with steroids. The liver transplant recipient (patient
6, Supplementary Table 1) had a mild rejection episode
treated with steroids.Wilson’s disease [40] 1
Mevalonic aciduria [22] 1
Hyper-IgM syndrome with
cirrhosis [41]
1
Glycogen storage disease 1
Biliary atresia 1
Chemical-induced failure 1
Failure of unknown etiology 1
Kidney
Glomerulonephritis/sclerosis [42-44] 3
IgA nephropathy 2
Lung
Idiopathic pulmonary ﬁbrosis 1
Solid organ donor
Cadaver 20 7
HLA “matched” sibling 2
HLA mismatched sibling 1
Parent 3
Child 1
Spouse 1
IST for SOT
CSP 3
CSP þ prednisone þ/ other* 4 3
Azathioprine þ prednisone 3
Tacrolimus þ prednisone 7
Tacrolimus þ prednisone þ othery 3 4
Tacrolimus þ MMF þ basiliximab 2 1
Tacrolimus þ other unspeciﬁed 5
Unknown
Duration SOT to hematologic diagnosis, yr
Median, range .4 (0-14)z 2.9 (.1-9.4)
Duration SOT to HCT, yr
Median, range 1.5 (.06-19)z 3.5 (.4-10.0)
Hematologic diagnosis
Aplastic anemia 11 2
ALL 1 1
AML 3 2
EPP 2
GVHD with graft failure 1
HLH 1
Hyper-IgM 1
MDS 2 2
Mevalonic aciduria 1
Myeloﬁbrosis 1
PTLD/MDS 1
T cell PTLD, EBV negative 2
T cell hepatosplenic lymphoma 1
HCT conditioning regimen
Bu/Cy 3
Bu/Cy þ other 3
(Continued on next page)Allogeneic HCT after SOT
Twenty-seven patients were identiﬁed in the literature
who received allogeneic HCT after SOT (Table 2). These pa-
tients were transplanted between 1991 and 2012. Median
patient age at the time of SOT was 10 years. All patients
received only 1 solid organ (liver¼ 19, heart¼ 5, kidney¼ 3).
Five liver transplants were from living donors, and 2 kidney
transplants were from HLA-matched siblings. Except for the
HLA-matched siblings and haploidentical parental trans-
plants, patientedonor HLA disparity was not reported. IST
after SOT included prednisone and a calcineurin inhibitor in
most patients.
The indications for SOT and allogeneic HCT were identical
in 5 patients, 2 with erythropoietic protoporphyria, 1 with
hemophagocytic lymphohistiocytosis, 1 with mevalonic
aciduria, and 1 with hyper-IgM syndrome. Of the remaining
22 patients, 11 developed AA, 10 after hepatitis and 1 asso-
ciated with Wilson’s disease. The median time from SOT to
AAwas 3.5 months. The median time from SOT to HCT for AA
was 7months. Ten patients developed amyeloid or lymphoid
hematologic malignancy. The median times from SOT to the
hematologic malignancy and from SOT to HCT were 8 and 8.7
years, respectively. One patient was transplanted for acute
graft-versus-host disease (GVHD) and marrow failure 1.4
months after a liver transplant [34].
Allogeneic transplant conditioning regimens included
both myeloablative and reduced-intensity regimens. Most
patients (7/11) with AA received chemotherapy-only regi-
mens. Of the patients with hematologic malignancies, 5
received busulfan/cyclophosphamide, 2 received cyclophos-
phamide/total body irradiation, and 3 were given
ﬂudarabine-based regimens. Twenty patients had related
donors, with 13 stated to be HLA-matched siblings. Seven
had unrelated donors, 3 of whom were HLA-matched. Thir-
teen patients received stem cells procured by marrow har-
vest, 5 received PBSC products, and 2 received cord blood.
Three patients received more than 1 stem cell source. The
stem cell source was unstated in 4 patients. Of 24 patients
whose GVHD prophylaxis was noted, 22 received calcineurin
inhibitors plus prednisone, methotrexate, or mycophenolate
mofetil. Two patients received alemtuzumab-based
Table 2
(continued)
Literature
Review
FHCRC
Cy/TBI 3 1
Cy/TLI 4
Cy/ATG or Cy/ALS 3 2
Flu/Bu 2
Flu/Cy/ATG 2
Flu/TBI 1 1
Flu/melphalan þ/ other 4
Flu/treosulfan/ATG þ other 1
Flu/Bu/rabbit ATG 2
ATG 1
Clofarabine/TBI 1
Treosulfan, ﬂudarabine, TBI 1
HCT donor
“Matched” sibling 12 4
“Haploidentical” family memberx 7
“Matched” unrelated donor 3 4
Mismatched unrelated donor 2
Cord blood 2
Mismatched related donor 1
Stem cell source
BM 13 3
PBSC 5 5
CB 2
CB þ BM 1
BM þ PBSC boost 1
BM-MSC þ PBSC 1
Unknown 4
HCT IST
CSP þ/ prednisone 4
CSP, MMF 2 2
CSP, MTX þ/ prednisone 7 3
Tacrolimus þ/ prednisone 3
Tacrolimus, MMF þ/ prednisone 3 1
Tacrolimus, MTX 2
Tacrolimus, MTX, prednisoneþ/ other 2
Tacrolimus, prednisone, R-ATG, CSP 1
Alemtuzumab þ/ other 2
Unknown 3
Survival after HCT, yr
Median, range 1.0 (.1-8.0) 2.4 (.4-23.1)
Cause of death (n ¼ 8)
Solid organ rejection (heart) 1
Infection 4
Multiorgan failure 2
Persistent ALL, GVHD 1
Relapse of hematologic disease 4
EPP indicates erythropoietic protoporphyria; HLH, hemophagocytic lym-
phohistiocytosis; ALL, acute lymphoblastic leukemia; AML, acute myeloge-
nous leukemia; MDS, myelodysplastic syndrome; Bu, busulfan; Cy,
cyclophosphamide; TBI, total body irradiation; TLI, total lymphoid irradia-
tion; ALS, antilymphocyte serum; Flu, ﬂudarabine; BM, bone marrow; CB,
cord blood, MSC, mesenchymal cells; MTX, methotrexate.
* Azathioprine ¼ 2; azathioprine þ OKT3 ¼ 1.
y Basiliximab ¼ 1; azathioprine and MMF ¼ 1; azathoiprine and
daclizumab ¼ 1; MMF, CY and sirolimus ¼ 1; thymoglobulin ¼ 1; MMF ¼ 1.
z Based on 26 patients.
x Mother ¼ 3; father ¼ 1; son ¼ 2; unknown ¼ 1.
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or graft rejection: 2 had second hematopoietic transplants
(described below) and 1 had autologous marrow recovery.
Nineteen patients were alive from .3 to 8.0 years after HCT.
Eight patients died between .1 and 1.0 year after HCT. The
most frequent cause of death was infection, with 1 patient
dying from solid organ graft (heart) rejection.
Four allogeneic transplant recipients received 2 hemato-
poietic transplants. One patient with amyloidosis received an
autologous HCT 2 years before a heart transplant [45]. Six
months after SOT, an unrelated donor bone marrow trans-
plant (BMT) was performed because of disease progressionto stage 1 myeloma. The patient was alive 1.5 years after the
allogeneic HCT with no evidence of cardiomyopathy,
although a post-transplant cardiac biopsy was positive for
amyloid. One patient who received a liver transplant for
hepatitis-associated hepatic failure developed severe AA 4
months after SOT [33]. An HLA-matched sibling BMT was
rejected 2.5 months after BMT. A second BMTwas performed
using the same donor 4 months after the ﬁrst BMT, and long-
term engraftment was achieved. The patient was doing well
8 years after the second BMT. A patient with erythropoietic
protoporphyria initially received a cadaveric liver transplant
followed by an HLA-matched sibling BMT 6 months later
[36]. Seven months after BMT, a PBSC transplant from the
same sibling resulted in sustained hematopoietic engraft-
ment. The fourth patient underwent a liver transplant for
treatment of Wilson’s disease [40]. Within 5 months the
patient developed severe AA unresponsive to IST. Nine
months after the liver transplant, the patient received a
mismatched, unrelated donor BMT but failed to engraft.
Fourteenmonths after liver transplant, a PBSC transplant was
performed using a mismatched, unrelated donor. Twenty
months after PBSC transplantation the patient was alive with
full engraftment.
Between April 1989 and November 2012, 8 FHCRC pa-
tients underwent allogeneic HCT after SOT (Table 2 and
Supplementary Table 2). Median patient age at SOT was 15.6
years. Seven patients received a cadaveric SOT, and 1
received a living, unrelated donor SOT. Themedian time from
SOT to allogeneic HCTwas 3.5 years. Two patients had kidney
transplants for IgA nephropathy, 1 of whom also had
Henoch-Schönlein purpura. Five patients received liver
transplants for glycogen storage disease (n ¼ 1); drug-
induced hepatic failure (n ¼ 1); non-A, non-B hepatitis
(n¼ 1); congenital biliary atresia (n¼ 1); or hepatic failure of
unknown etiology (n ¼ 1). One patient received a double-
lung transplant for idiopathic pulmonary ﬁbrosis. All pa-
tients received a calcineurin inhibitor plus 1 to 3 additional
immunosuppressive drugs at the time of their SOT.
The indication for HCT was a myeloid malignancy in 4
patients, a lymphoid malignancy in 2 patients, and AA in 2
patients. Median time from SOT to the hematologic diagnosis
was 2.9 years. Median time from the hematologic diagnosis
to allogeneic HCT was .5 years. Conditioning regimens used
were based on the hematologic diagnosis, patient age, and
donor type. Two AA patients received horse antithymocyte
globulin plus cyclophosphamide, 4 patients with myeloid
malignancies received ﬂudarabine-based regimens, the
acute lymphoblastic leukemia patient received clofarabine/
200 rad total body irradiation, and 1 patient with T cell
lymphoma received cyclophosphamide/1200 rad total body
irradiation. Four donors were HLA-matched siblings and 4
were HLA-matched, unrelated donors. Stem cells were ob-
tained by bone marrow harvest for 3 patients (AA ¼ 2, acute
lymphoblastic leukemia ¼ 1) and PBSC collection for 5 pa-
tients. GVHD prophylaxis included cyclosporine or tacroli-
mus plus methotrexate or mycophenolate mofetil. Four
patients were alive as of the date of last contact, and 4 died,
.4, .6, 1.5, and 3.4 years, respectively, after HCT. Median sur-
vival after HCT was 2.4 years. All deaths were associated with
relapse of the hematologic malignancy.
One patient (no. 14, Supplementary Table 2) rejected her
ﬁrst kidney graft 1.9 years after the kidney transplant and 26
days after HCT. At the time of rejection she had low normal
tacrolimus levels and only mild skin GVHD treated with
topical steroids. She developed BK cystitis proximate to her
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a second kidney transplant from an HLA haploidentical sister,
2.9 years after her HCT. She is alive 3.7 years after HCT with
good renal function and no evidence of hematologic relapse.
All allogeneic HCT recipients had prompt neutrophil and
platelet engraftment. Median time to an absolute neutrophil
count> .5109/L for 2 consecutive days was day 20. Median
time to an untransfused platelet count  20  109/L for 7
consecutive days was day 14. No patient developed docu-
mented sinusoidal obstructive syndrome. By day 28
maximum serum bilirubin ranged from .6 to 4.5 mg/dL with
a median of 1.1. Renal function during the ﬁrst month after
HCT was stable in 6 of 8 patients with a maximum serum
creatinine of .3 to 1.7 mg/dL. As noted above, 1 renal trans-
plant recipient rejected her ﬁrst kidney graft by day 26 after
HCT. The lung transplant recipient developed reversible,
acute kidney injury associated with calcineurin inhibitor
therapy.
Six patients developed acute GVHD. Four patients had
grades I to II GVHD of the skin only. One patient developed
grade II gut GVHD. The sixth patient, who had a prior liver
transplant, developed grade III skin GVHD followed by
biopsy-proven liver GVHD. All 6 patients were successfully
treated with corticosteroids dosed at 1 to 2 mg/kg predni-
sone daily in addition to their standard GVHD prophylaxis. At
the time of chronic GVHD evaluation, between days 72 and
103 after transplantation, none of the allogeneic transplant
recipients had chronic GVHD requiring additional IST. Of the
4 surviving patients, only 1 received a short increase of IST
for ocular and oral symptoms of chronic GVHD.
DISCUSSION
Our results, together with published literature, suggest
that HCT is feasible in patients who have had a prior SOT, and
there is no evidence to date that outcomes are affected by the
SOT [46,47]. The major indication for autologous HCT in pa-
tients after SOT was PTLD. An increased incidence of PTLD
has been associated with SOTs that require a greater degree
of immunosuppression (eg, heart, lung, and multiorgan
transplants) [48]. In our combined data, 12 of 16 patients
who underwent autologous HCT for PTLD were alive .5 to 5.5
years after HCT.
Indications for allogeneic HCT were more varied. In 14
cases the transplant was performed for AA, and 12 of these
patients were alive .5 to 23 years after HCT. Among 16 pa-
tients transplanted for a variety of hematologic malig-
nancies, 6 were reported alive at the time of last report, with
disease recurrence the major reason for failure. Of 7 patients
with genetic diseases who received liver transplants, the
genetic disease was the indication for both the SOT and HCT
in 5. Four of these patients were alive .3 to 2.5 years after
HCT, and 1 died from multiorgan failure .7 years after HCT.
Based on these results in a small number of patients,
transplanted organs do not appear to be uniquely sensitive
to high-dose HCT regimens. We saw no evidence that a prior
SOT increased the chance for marrow graft rejection. There
was also no evidence that a subsequent allogeneic he-
matopoietic cell graft increased the risk of solid organ graft
rejection.
Special considerations for patients undergoing allogeneic
HCT after SOT include choosing an appropriate HCT donor
and managing immunosuppression. Few data are available
regarding the degree of HLA disparity between the patient
and solid organ donor in the published literature. Among our
8 allogeneic HCT recipients, solid organ HLA typing wasavailable for 6 patients. Of 4 patients whose organ donors
had HLA-A, -B, -C, -DR, and -DQ typing, 2 were mismatched
for 7/10 HLA antigens and 2 for 9/10 antigens. Of 2 patients
whose organ donors had HLA-A, -B, -DR, and -DQ typing
available, 1 was 3 HLA antigens mismatched and 1 was 6 HLA
antigens mismatched with the recipient. As per standard
HCT practice, fully matched (10/10) related or unrelated HCT
donors were identiﬁed. All 6 patients had sustained he-
matopoietic engraftment, and only 1 patient had irreversible
rejection of the solid organ graft after HCT.
Because most SOTs use cadaveric donor organs, any
sharing of HLA antigens between the recipient and the solid
organ is random. HLA typing of the solid organ is often
incomplete. In contrast, HLA “matching” between the recip-
ient and the hematopoietic stem cell donor is often possible.
Based on our experience, albeit in a small number of patients,
the degree of HLA disparity between the patient, solid organ,
and hematopoietic stem cell source is not problematic.
Although most of our patients developed acute GVHD, none
had fatal GVHD and chronic GVHD did not impact long-term
survival. Only 1 patient had rejection of the solid organ
(“graft-versus-graft”), and whether this was directly related
to the allogeneic HCT is difﬁcult to know.
In the published literature management of IST during
conditioning therapy for HCT was variable and often not
stated. In our population of autologous transplant recipients,
the IST prescribed for SOT was usually continued during the
HCT conditioning regimen. The duration of IST after the
autologous transplant was dictated by the status of the SOT.
For patients who received myeloablative allogeneic trans-
plants, IST was discontinued during conditioning and restar-
ted on day 1. For patients who received reduced-intensity
conditioning, IST drugs and levels were dosed per our stan-
dard GVHD prophylaxis protocols. For allogeneic transplant
recipients the duration of ISTwasmanaged jointly by both the
hematopoietic and solid organ transplant teams.
In summary, given the available data on a small number of
patients, HCT after SOT can be performed successfully for a
variety of indications. Although most allogeneic HCTs used
HLA-matched sibling donors, both HLA-mismatched, related
and unrelated donors (including cord blood) can be consid-
ered. Rejection episodes of the solid organ have occurred
rarely and were usually reversed with a temporary increase
in IST. Hematopoietic graft failure is also unusual but may
necessitate a second HCT. In carefully selected patients,
multiple solid organ or hematopoietic transplants have been
successful. GVHD has not been a limiting factor in either
HLA-matched or -mismatched donor HCT. Themajor cause of
death in both autologous and allogeneic HCT recipients is
persistence or relapse of hematologic disease. More sys-
tematic follow-up is needed to further deﬁne the optimal
approach to caring for these patients.
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